Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in <i>Drosophila</i>.

ABSTRACT:

Introduction

Intestinal stem cells (ISCs) possess the ability to self-renew and differentiate, which is essential for maintaining intestinal tissue homeostasis. However, their functionality significantly declines with age, leading to diminished tissue regeneration and an increased risk of age-associated diseases.

Methods

This study investigates the effects of Dapagliflozin (DAPA), a novel insulin sensitizer and SGLT2 inhibitor, on aging ISCs using the Drosophila melanogaster model. Our findings demonstrate that DAPA can inhibit the MAPK signaling pathway, as confirmed by network pharmacology analysis and molecular docking experiments.

Results

DAPA ameliorates ISC aging, improves intestinal function (including enhanced fecal excretion, restored intestinal barrie

SUBMITTER: Yan J 

PROVIDER: S-EPMC12055793 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature